Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
Status:
Completed
Trial end date:
2019-12-28
Target enrollment:
Participant gender:
Summary
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when
administered twice daily for 4 weeks using success rate in Investigator's Global Assessment
(IGA) at Week 4 as the primary endpoint in adult patients with AD.